Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lonza Innovation Showcase Features Novel Culture System at ISSCR

Published: Saturday, June 21, 2014
Last Updated: Saturday, June 21, 2014
Bookmark and Share
Company has introduced L7™ hiPSC reprogramming and hPSC culture system at ISSCR.

Lonza has introduced its new L7™ hiPSC Reprogramming and hPSC Culture System for basic stem-cell research, disease modeling, drug development and regenerative medicine at ISSCR, in Vancouver, Canada.

Lonza’s highlighted offering includes innovative tools to simplify and streamline the stem-cell culturing and reprogramming workflow. The novel L7™ Culture System supports the generation of reproducible, clinically relevant data as a solid basis for more efficient drug development and accelerated progress in regenerative medicine.

The L7™ stem-cell reprogramming and culture system includes seven key components that are aligned and function as a robust workflow:

1. Primary cells, including disease phentoypes
2. Nucleofector™ Technology
3. hPSC Reprogramming Kits
4. hPSC Medium
5. hPSC Matrix
6. hPC Passaging Solution
7. hPSC Cryosolution

This novel culture system is the only available complete solution for the generation of induced pluripotent stem-cells (iPSCs), the maintenance of human embryonic stem-cells (hESCs) and iPSCs under defined, xeno-free conditions. The culture system allows for every other day feeding and supports long term culture and maintenance of hPSCs. The L7™ System thus provides a seamless transition from the lab bench to clinical development applications.

Highlighting their new advancements, Lonza will host the Innovation Showcase “Bridging Research to Therapy: Novel iPSC Tools and Technologies” on Thursday, 19 June, 11:30am - 12:30 pm, in the West Ballroom B, Level # 1.

During the one hour symposium, three renowned speakers will describe different approaches to overcome hiPSC challenges. To learn more about L7™ and Lonza’s Innovation Showcase, visit www.lonza.com/isscr.

Speakers and topics are:

• “From the Nobel Prize to the Clinic: One Step Closer to iPSC-Based Therapies”, Behnam Ahmadian Baghbaderani, Ph.D., Lonza Walkersville, Cell Therapy Development Services

• “Lonza L7™ Reprogramming and Cell Culture System - A Case Study”, Yu-Chieh Wang, Ph.D., Senior Research Associate, Center for Regenerative Medicine, The Scripps Research Institute

• “Highly Efficient and Specific Human Genome Editing in iPSCs Using CRISPR-Cas9 System”, Linzhao Cheng, Ph.D., Professor of Medicine and Oncology Stem Cell Program in the Institute for Cell Engineering, Johns Hopkins School of Medicine


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lonza Acquires Viral Vaccine and Vector Manufacturer Vivante GMP Solutions
Lonza expands its custom service platform to viral vaccines and gene therapy vectors.
Tuesday, August 31, 2010
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
Lonza provides process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System™.
Wednesday, June 17, 2009
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!